



**For Immediate Release**

**EVOKE PHARMA, INC. ANNOUNCES SUCCESSFUL PHARMACOKINETIC TRIAL RESULTS FOR EVK-001**

**SAN DIEGO, CA (June 15, 2008)** – Evoke Pharma, Inc. announced today the successful completion of a phase 1 clinical trial for EVK-001. The goal of the trial was to evaluate an optimized formulation previously in phase 2 clinical studies. The formulation was evaluated against other currently marketed versions of the same agent. EVK-001 is a unique formulation of a currently approved agent for the symptomatic treatment of diabetic gastroparesis.

“This is Evoke’s initial product development program, so we are very pleased with the positive results of the PK trial,” stated Dave Gonyer, CEO for Evoke Pharma. “This data will allow Evoke to accelerate the development of EVK-001 into pivotal trials. We believe EVK-001 could provide a significant improvement for patients with gastroparesis.”

Evoke intends to discuss these results and a phase 3 trial strategy at an End-of-Phase 2 Meeting with the FDA in October. The product has been successfully tested in a phase 2 clinical trial, and with agency approval the company expects to initiate pivotal trials in 2009.

**About Evoke Pharma, Inc.**

Evoke Pharma, Inc. is a privately held, specialty pharmaceutical company headquartered in San Diego, CA focused on acquiring and developing products to treat gastrointestinal and related disease. Evoke is currently developing EVK-001 for the treatment of symptoms of diabetic gastroparesis. Its lead development compound is in preparations for phase 3 clinical testing. Evoke holds rights to intellectual property associated with EVK-001 granted by the United States Patent & Trademark Office with expiration dates through 2021.

**About Gastroparesis**

Gastroparesis is a common gastrointestinal problem affecting approximately 8 million Americans. The disease refers to delayed gastric emptying, in the absence of mechanical obstruction of the pylorus and duodenum, and is associated with a variety of symptoms. Patients may experience symptoms of: postprandial nausea and vomiting, particularly vomiting of food ingested several hours previously; epigastric pain and burning, upper abdominal distention (bloating), early satiety, bitter or acid regurgitation, belching and anorexia. In more severe forms, the disease may lead to poor nutrition and dehydration with the patient ultimately receiving treatment in a hospital.

Further information regarding Evoke is available at [www.EvokePharma.com](http://www.EvokePharma.com).

###

Evoke Pharma, Inc. Contact:  
Matt D’Onofrio  
EVP, Corporate Development  
858-967-5454